Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Glucose transporters GLUT1 and GLUT3 are key members of the solute carrier family 2 (SLC2A) that facilitate the passive diffusion of glucose across plasma membranes [1.1.1, 1.1.3]. GLUT1 is ubiquitously expressed and serves as the primary transporter responsible for glucose delivery across the blood-brain barrier, while GLUT3 is predominantly found in neurons and possesses a high affinity for glucose to meet high metabolic demands [1.1.4, 1.3.3]. In many cancers, these transporters are significantly upregulated to facilitate the increased glucose consumption required for rapid proliferation, a phenomenon known as the Warburg effect [1.2.2, 1.2.3]. Consequently, GLUT1 and GLUT3 are prominent therapeutic targets in oncology, with various small-molecule inhibitors like BAY-876 and WZB117 being developed to disrupt tumor energy metabolism [1.3.2, 1.4.2]. Beyond cancer, mutations in the SLC2A1 gene cause GLUT1 deficiency syndrome, leading to severe neurological symptoms due to impaired brain glucose supply [1.1.2, 1.4.1]. Conversely, reduced expression of both GLUT1 and GLUT3 has been implicated in the pathogenesis of neurodegenerative disorders such as Alzheimer's disease [1.2.1, 1.3.4]. Therapeutic interventions targeting these transporters must carefully balance efficacy against the risk of systemic hypoglycemia and neuroglycopenia [1.4.1]. Additionally, GLUT1 serves as a receptor for human T-cell leukemia viruses (HTLV-I and II), adding another layer to its biological significance [1.1.2].
Inhibition of facilitated glucose transport, blockade of glycolytic metabolism, and chemo-radiosensitization of tumor cells [1.2.3, 1.3.2].
7 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Solute carrier family 2, facilitated glucose transporter member 1 (GLUT1) and Solute carrier family 2, facilitated glucose transporter member 3 (GLUT3) (GLUT1 and GLUT3).